Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

MLA

Juan P. Frias, et al. “Once-Weekly Tirzepatide versus Once-Daily Insulin Degludec as Add-on to Metformin with or without SGLT2 Inhibitors in Patients with Type 2 Diabetes (SURPASS-3): A Randomised, Open-Label, Parallel-Group, Phase 3 Trial.” Lancet (London, England), vol. 398, no. 10300, June 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....83a350204bbe4360a796186dfbe98cc9&authtype=sso&custid=ns315887.

APA

Juan P. Frias, Bernhard Ludvik, Ross Bray, Laura Fernández Landó, Esteban Jódar, Francesco Giorgino, Ángel Rodríguez, & Katelyn Brown. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet (London, England), 398(10300).

Chicago

Juan P. Frias, Bernhard Ludvik, Ross Bray, Laura Fernández Landó, Esteban Jódar, Francesco Giorgino, Ángel Rodríguez, and Katelyn Brown. 2021. “Once-Weekly Tirzepatide versus Once-Daily Insulin Degludec as Add-on to Metformin with or without SGLT2 Inhibitors in Patients with Type 2 Diabetes (SURPASS-3): A Randomised, Open-Label, Parallel-Group, Phase 3 Trial.” Lancet (London, England) 398 (10300). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....83a350204bbe4360a796186dfbe98cc9&authtype=sso&custid=ns315887.